Genetic Variation in IGFBP2 and IGFBP5 is Associated with Breast Cancer in Populations of African Descent

Overview

Journal Hum Genet

Specialty Genetics

Date 2008 Jan 23

PMID 18210156

Citations 19

Authors

Chad P Garner

Yuan C Ding

Esther M John

Sue A Ingles

Olufunmilayo I Olopade

Dezheng Huo

Clement Adebamowo

Temidayo Ogundiran

Susan L Neuhausen

Affiliations

Soon will be listed here.

Abstract

The insulin-like growth factor (IGF) signaling pathway is thought to play a major role in the etiology of breast cancer. Although incidence rates of breast cancer overall are lower in African Americans than in Caucasians, African-American women have a higher incidence under age 40 years, are diagnosed with more advanced disease, and have poorer prognosis. We investigated the association of breast cancer and genetic variants in genes in the IGF signaling pathway in a population-based case-control study of African-American women. We found significant associations at a locus encompassing parts of the IGFBP2 and IGFBP5 genes on chromosome 2q35, which we then replicated in a case-control study of Nigerian women. Based on those initial findings, we genotyped a total of 34 single nucleotide polymorphisms (SNPs) across the region in both study populations. Statistically significant associations with breast cancer were observed across approximately 50 kb of DNA sequence encompassing three exons in the 3' end of IGFBP2 and three exons in the 3' end of IGFBP5. SNPs were associated with breast cancer risk with P values as low as P = 0.0038 and P = 0.01 in African-Americans and Nigerians, respectively. This study is the first to report associations between genetic variants in IGFBP2 and IGFBP5 and breast cancer risk.

Citing Articles

Deletion of endothelial IGFBP5 protects against ischaemic hindlimb injury by promoting angiogenesis.

Song F, Hu Y, Hong Y, Sun H, Han Y, Mao Y Clin Transl Med. 2024; 14(6):e1725.

PMID: 38886900 PMC: 11182737. DOI: 10.1002/ctm2.1725.

Comprehensive Analyses and Experiments Confirmed IGFBP5 as a Prognostic Predictor Based on an Aging-genomic Landscape Analysis of Ovarian Cancer.

Fan T, Xu L, Zhang H, Peng J, Liu D, Zou W Curr Cancer Drug Targets. 2023; 24(7):760-778.

PMID: 38018207 DOI: 10.2174/0115680096276852231113111412.

Biological effects and regulation of IGFBP5 in breast cancer.

Dittmer J Front Endocrinol (Lausanne). 2022; 13:983793.

PMID: 36093095 PMC: 9453429. DOI: 10.3389/fendo.2022.983793.

ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin.

Kamran M, Bhattacharya U, Omar M, Marchionni L, Ince T NPJ Breast Cancer. 2022; 8(1):99.

PMID: 36038558 PMC: 9424319. DOI: 10.1038/s41523-022-00474-2.

The African Female Breast Cancer Epidemiology Study Protocol.

Ezeome E, Yawe K, Ayandipo O, Badejo O, Adebamowo S, Achusi B Front Oncol. 2022; 12:856182.

PMID: 35494056 PMC: 9044037. DOI: 10.3389/fonc.2022.856182.

References

Canzian F, McKay J, Cleveland R, Dossus L, Biessy C, Rinaldi S . Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer. 2006; 94(2):299-307. PMC: 2361124. DOI: 10.1038/sj.bjc.6602936. View

Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A . Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999; 22(5):436-40. DOI: 10.1097/00000421-199910000-00002. View

Yu H, Jin F, Shu X, Li B, Dai Q, Cheng J . Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2002; 11(8):705-12. View

John E, Hopper J, Beck J, Knight J, Neuhausen S, Senie R . The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004; 6(4):R375-89. PMC: 468645. DOI: 10.1186/bcr801. View

Flint D, Beattie J, Allan G . Modulation of the actions of IGFs by IGFBP-5 in the mammary gland. Horm Metab Res. 2004; 35(11-12):809-15. DOI: 10.1055/s-2004-814164. View

Missmer S, Haiman C, Hunter D, Willett W, Colditz G, Speizer F . A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer. 2002; 100(3):332-6. DOI: 10.1002/ijc.10473. View

Setiawan V, Cheng I, Stram D, Penney K, Le Marchand L, Altshuler D . Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006; 15(1):172-4. DOI: 10.1158/1055-9965.EPI-05-0625. View

Swanson G, Lin C . Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr. 1994; (16):69-77. View

Hankinson S, Willett W, Colditz G, Hunter D, Michaud D, Deroo B . Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351(9113):1393-6. DOI: 10.1016/S0140-6736(97)10384-1. View

10.

English W, Cleveland K, Barber W . There is no difference in survival between African-American and white women with breast cancer. Am Surg. 2002; 68(6):594-7. View

11.

Chapman J, Clayton D . One degree of freedom for dominance in indirect association studies. Genet Epidemiol. 2007; 31(3):261-71. DOI: 10.1002/gepi.20207. View

12.

John E, Horn-Ross P, Koo J . Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 Pt 1):1143-52. View

13.

Pereira J, Meyer T, Docherty S, Reid H, Marshall J, Thompson E . Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 2004; 64(3):977-84. DOI: 10.1158/0008-5472.can-03-3056. View

14.

Becker M, Sommer A, Kratzschmar J, Seidel H, Pohlenz H, Fichtner I . Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 2005; 4(1):151-68. View

15.

Wang W, John E, Ingles S . Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev. 2005; 14(12):2990-4. DOI: 10.1158/1055-9965.EPI-05-0310. View

16.

Schernhammer E, Hankinson S, Hunter D, Blouin M, Pollak M . Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer. 2003; 107(1):60-4. DOI: 10.1002/ijc.11358. View

17.

Cheng I, Penney K, Stram D, Le Marchand L, Giorgi E, Haiman C . Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1993-7. DOI: 10.1158/1055-9965.EPI-06-0361. View

18.

Sachdev D, Yee D . The IGF system and breast cancer. Endocr Relat Cancer. 2001; 8(3):197-209. DOI: 10.1677/erc.0.0080197. View

19.

Butt A, Dickson K, McDougall F, Baxter R . Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem. 2003; 278(32):29676-85. DOI: 10.1074/jbc.M301965200. View

20.

Adebamowo C, Ogundiran T, Adenipekun A, Oyesegun R, Campbell O, Akang E . Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol. 2003; 13(6):455-61. DOI: 10.1016/s1047-2797(02)00426-x. View